First prospectively-designed outcome study in estrogen receptor (ER)+ breast cancer (BC) patients (pts) with N1mi or 1-3 positive nodes in whom treatment decisions in clinical practice incorporated the 21-gene recurrence score (RS) result
Salomon M. Stemmer(Tel Aviv University), Noa Ben-Baruch(Kaplan Medical Center), Lior Soussan‐Gutman(Teva Pharmaceuticals (Israel)), Kim L. Isaacs(University of North Carolina at Chapel Hill), Nicky Liebermann(Clalit Health Services), M. Steiner(Sheba Medical Center), Shulamit Rizel(Rabin Medical Center), Steven Shak(Genomic Health (United States)), Cecilia Svedman(Lund University), Avital Bareket‐Samish, Tamar Peretz(Hadassah Medical Center), Bella Nisenbaum(Meir Medical Center), Ora Rosengarten(Sheba Medical Center), D. Geffen(Sheba Medical Center), Georgeta Fried(Roche (Switzerland))
Cited by 3
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
|Gynecologic Oncology|2015|301
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
|JAMA Oncology|2021|291
ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin
|Nature Biotechnology|2021|169